Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, yellow fever, and rabies vaccines. In addition, the company has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Innate Pharma SA for a natural killer cell engager program targeting B7-H3; and Blackstone Life Sciences to develop pivotal studies and clinical development program. Further, it has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop novel targeted protein degradation therapies; Denali Therapeutics Inc. to treat a range of systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for the discovery and development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Sanofi

Sanofi ( ($SNY) ) just unveiled an update. In December 2025, Sanofi announced the completion of its acquisition of Vicebio Ltd, which enhances its ...

Sanofi Expands Vaccine Portfolio and Gains China Approval for Rare Disease Drugs

These are the upcoming stock splits for the week of December 8 to December 12, based on TipRanks’ Stock Splits Calendar. A stock split is a corpora...

Upcoming Stock Splits This Week (December 8 to December 12) – Stay Invested

Bernstein analyst Florent Cespedes maintained a Buy rating on Sanofi today and set a price target of €119.00. According to TipRanks, Cespedes is a ...

Bernstein Sticks to Its Buy Rating for Sanofi (SNYNF)

Polestar Automotive Holding UK PLC Sponsored ADR Class C ( ($PSNYW) ) has issued an update. On December 4, 2025, Polestar Automotive Holding UK PLC...

Polestar Announces ADS Ratio Change Effective December 9, 2025

An update from Sanofi ( ($SNY) ) is now available. On November 25, 2025, Sanofi and Regeneron announced that the European Commission approved Dupix...

Sanofi’s Dupixent Gains EU Approval for Chronic Urticaria

British drugmaker AstraZeneca ($AZN), fresh off a record-high stock price, continues to draw interest from U.S. and European investors thanks to, a...

Is AstraZeneca’s Stock (AZN) a Good Investment Right Now?

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Sanofi (SNYNF – Research Report) and CSPC Pharmaceut...

Analysts Are Bullish on These Healthcare Stocks: Sanofi (SNYNF), CSPC Pharmaceutical Group (CHJTF)

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Buy rating on Sanofi, with a price target of €110.00. According to T...

Sanofi (SNYNF) Receives a Buy from Deutsche Bank

Naspers Limited ( ($NPSNY) ) has released its Q2 earnings. Here is a breakdown of the information Naspers Limited presented to its investors. Naspe...

Naspers Limited Reports Strong Growth in 2025 Earnings

In a report released today, Benjamin Jackson CFA from Jefferies maintained a Buy rating on Sanofi, with a price target of €100.00. Jackson CFA cove...

Jefferies Sticks to Its Buy Rating for Sanofi (SNYNF)

Sanofi ( ($SNY) ) just unveiled an update. In November 2025, Sanofi announced significant advancements in its pharmaceutical offerings. On November...

Sanofi Advances with Dupixent and Teizeild Approvals in November 2025

Polestar Automotive Holding UK PLC Sponsored ADR Class C ( ($PSNYW) ) has released its Q3 earnings. Here is a breakdown of the information Polestar...

Polestar Reports Strong Revenue Growth Amid Challenges

Polestar Automotive Holding Uk Plc Adr ( ($PSNY) ) has released its Q3 earnings. Here is a breakdown of the information Polestar Automotive Holding...

Synergy Chc Corp (($SNYR)) has held its Q3 earnings call. Read on for the main highlights of the call. The recent earnings call for Synergy CHC Cor...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SNY	$48.68	-0.37%	2.25M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SNY	$48.68	-0.4%	2.25M
3
4
5
6

SNY

SNY

Get Sanofi Data in Excel

Get Sanofi Data in Excel